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ABSTRACT
Background. Metastasis to the thyroid gland from non-
thyroid sites is an uncommon clinical presentation in
surgical practice. The aim of this review was to assess its
incidence management and outcomes.
Methods. A literature review was performed to identify
reports of metastases to the thyroid gland. Both clinical and
autopsy series were included.
Results. Metastases to the gland may be discovered at the
time of diagnosis of the primary tumor, after preoperative
investigation of a neck mass, or on histologic examination
of a thyroidectomy specimen. The most common primary
tumors in autopsy studies are from the lung. In clinical
series, renal cell carcinoma is most common. For patients
with widespread metastases in the setting of an aggressive
malignancy, surgery is rarely indicated. However, when
patients present with an isolated metastasis diagnosed
during follow-up of indolent disease, surgery may achieve
control of the central neck and even long-term cure. Other
prognosticators include features of the primary tumor, time
interval between initial diagnosis and metastasis, and
extrathyroid extent of disease.
Conclusions. In patients with thyroid metastases, com-
munication among clinicians treating the thyroid and the
index primary tumor is essential. The setting is complex,
and decisions must be made considering the features of the
primary tumor, overall burden of metastases, and comor-
bidities. Careful balancing of these factors influences
individualized approaches.
The earliest description of metastasis to thyroid gland is
attributed to Virchow, who described a testicular tumor
metastasis in 1871. Given the extensive blood supply to the
gland, the low incidence of metastases to the thyroid is
surprising1. Willis suggested that this is influenced by the
glandular microenvironment; the fast arterial blood flow
and high concentration of oxygen and iodine could thus
prevent the anchorage and secondary growth of circulating
tumor cells.1
While postmortem examination suggests that as many as
24% of patients who die of nonthyroid malignancies have
metastases to this gland, these seem rare in clinical prac-
tice.2–4 Although the majority (60–80%) of patients who
present with thyroid metastasis are diagnosed in the setting
of known previous malignancy, an occult primary tumor
accounts for a significant percentage (20–40%).4,5 In
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addition, some patients are diagnosed during preoperative
investigation, while others will be diagnosed on histologic
examination of a thyroidectomy specimen.
PRIMARY ORIGIN OF THYROID METASTASES
In autopsy series, the incidence of metastases overall is
2%. In autopsy series, the most common site of primary
tumor is the lung, whereas in clinical series renal cell car-
cinoma (RCC) is more common (Table 1).1,6–18 Because of
the aggressive nature of lung malignancies, patients are often
treated with palliative intent from an early stage, and
investigation for additional metastases is therefore curtailed.
In contrast, RCC is less aggressive, and patients are more
likely to be further investigated and treated for metastatic
disease. Metastasis to the thyroid should not be confused
with direct infiltration of the thyroid by locally aggressive
disease in the larynx or upper esophagus, as reported in some
series.19 Metastases can originate at almost any primary
site20–27 Figure 1 summarizes the most common primary
tumors reported in clinical series to metastasize to the thyroid
(Table 2).21,26,28–51
PREOPERATIVE INVESTIGATION
An accurate clinical history is significant. A prior
malignancy, as well as symptoms such as hematuria or
hemoptysis, may raise the possibility of an occult primary
tumor in the kidneys or lungs. However, many patients
with thyroid metastasis present with signs and symptoms
identical to those with primary thyroid disease. One study
indicates that 72% present with a palpable neck mass and
28% with an incidental lesion identified on imaging.52
Thyroid metastasis at an advanced stage within the central
neck may result in dysphagia and dysphonia, similar to
aggressive thyroid malignancy. Changes in thyroid func-
tion are late and relatively uncommon.5,53
The accuracy of thyroid imaging has improved with the
introduction of high-resolution ultrasound as well as cross-
sectional [computed tomography/magnetic resonance
imaging (CT/MRI)] and functional imaging [positron
emission tomography (PET)]. Nevertheless, even sophis-
ticated techniques cannot reliably differentiate between
primary thyroid lesions and metastases.28,54 Fine needle
aspiration cytology (FNAC) can often be of assistance.55,56
In the setting of metastatic lesions to the thyroid, FNAC
positive and negative predictive values of 89 and 93%,
respectively, have been reported, and application of
molecular markers (e.g., the BRAF growth promoter in
papillary thyroid cancer) and immunohistochemistry may
be of further help (e.g., CD-10 in RCC).25,57–59 There
limitations of cytology are acknowledged.29,56,60 Poorly
differentiated tumors such as aggressive anaplastic thyroid
cancers can be difficult to differentiate from-high grade
metastases.54,58,61,62 In addition, neck hematoma after
needle biopsy of RCC has anecdotally been seen and
should raise concerns for performing core biopsies of
lesions suspicious for RCC. Rare, and hence morphologi-
cally unfamiliar, tumors and lack of cellular differentiation
and expression of antigens conveniently detected by
TABLE 1 Frequency of metastasis to the thyroid gland in autopsy series
Study No. thyroid metastases/no. of autopsies % Most frequent site of primary tumor
Mu¨ller8 11/623 1.8 Not available
Symmers9 7/298 2.3 Not available
Kitain10 14/452 3.1 Not available
Willis1 9/170 5.2 Breast
Rice11 9/89 10.1 Not available
Abrahms et al.12 19/1000 1.9 Breast
Thorpe13 4/200 2 Not available
Hull14 10/59 16.9 Lymphoid tissue
Mortensen et al.15 18/467 3.9 Lymphoid tissue
Shimaoka et al.7 188/1980 9.5 Breast
Brierre and Dickinson16 14/53 26.4 Not available
Silverberg and Vidone77 15/62 24.2 Lung
Berge and Lundberg51 201/16294 1.25 Breast
Watanabe and Tsuchiya18 4/309 1.29 Lung
Moghaddam et al.6 4/2117 0.46 Lung
Total (mean) 527/24173 2 Lung
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FIG. 1 Total number of cases
of metastasis to thyroid reported
in literature stratified by site of
primary tumor
TABLE 2 Incidence of primary tumors metastasising to the thyroid and treatment as reported in clinical series
Study n Most frequent site of primary tumor Total thyroidectomy (%)
Mayo et al.42 19 Lung Not available
Elliot et al.34 14 Breast = lung 43
Wychulis et al.43 14 Kidney 14
Harcourt-Webster35 11 Skin 0
Pillay et al.44 10 Esophagus 10
Brady et al.36 14 Lung Not available
Ericsson et al.33 10 Kidney 70
Czech et al.32 12 Kidney 100
Ivy et al.37 30 Kidney Not available
Chacho et al.45 8 Blood 0
Smith et al.46 19 Breast 0
Michelow et al.47 21 Lung 0
Rosen et al.21 11 Lung 55
Nakhjavani et al.28 43 Kidney 21
Lam et al.38 79 Lung Not available
Chen et al.40 10 Kidney 50
De Ridder et al.26 6 Kidney 67
Dequanter et al.48 11 Lung 82
Wood et al.30 15 Kidney 47
Kim et al.29 22 Breast 9
Mirallie´ et al.49 29 Kidney 72
Cichon´ et al.31 17 Kidney 94
Gerges et al.39 7 Lung 0
Choi et al.50 46 Lung 0
Russell et al.41 17 Kidney 65
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immunohistochemistry account for some of the difficul-
ties.2,61 To increase the likelihood of a preoperative
diagnosis, more invasive investigations such as core or
open biopsy have been considered.4,30 Obviously, the
multidisciplinary team must have a high index of suspicion,
particularly in patients with a history of malignancy.
AIMS OF TREATMENT
Many patients who present with a thyroid metastasis
will be treated with palliative intent. For selected patients,
however, lobectomy or total thyroidectomy may be per-
formed, either with the aim of long-term cure or achieving
local control.31 A balance must be reached regarding the
course of systemic disease versus the likely outcome from
uncontrolled local disease. Because of the nature of
reported surgical series, the percentage of patients who
present with metastasis to the thyroid who are considered
candidates for surgery is unclear. Local invasion of thyroid
disease, irrespective of the source of malignancy, results in
dysphonia, dysphagia, hemoptysis, and stridor. Unfortu-
nately, few data exist on the frequency of presenting
symptoms. In addition, the patient’s fitness and comor-
bidities need to be weighed against the likelihood of
surgical success. The necessary close communication
between the teams involved in the management of primary
disease and thyroid is ensured by modern multidisciplinary
team management.
If the metastasis is confined within the thyroid gland
without evidence of significant extraglandular extension,
thyroidectomy may be performed with minimal morbidity.
In appropriately selected cases, the aim would be to pre-
vent asphyxia and hemoptysis associated with uncontrolled
disease in the central neck.32,33
In the case of a relatively indolent primary malignancy
present with an isolated thyroid metastasis presenting many
years after treatment for the index tumor, surgery with
curative intent is possible. Continuous communication
between the management teams positively influences
patient counseling and treatment planning.
PROGNOSTIC FACTORS
Although distant metastases are often an adverse prog-
nosticator, thyroid metastases may not have as poor an
outcome as those elsewhere.52 Nevertheless, 35 to 80% of
patients with thyroid involvement present with multiorgan
metastases.5,52,63
Overall prognosis appears to be most closely linked to
the innate features of the primary tumor.5 As already noted,
if the primary tumor is amenable to treatment with curative
intent, the subgroup of patients with isolated thyroid
metastasis would be candidates for curative treatment of
the metastasis as well.19,64 When considering thyroid sur-
gery in a palliative setting, the thyroid team should
consider the burden/volume of metastatic disease else-
where and the effect of extrathyroidal extension on surgical
morbidity, but individualized decisions are complex.65
For those patients with an indolent primary lesion and
disease confined to the thyroid gland without significant
extrathyroid extension, outcomes may be favorable. In
contrast, patients with aggressive primary disease, multi-
organ metastases, and invasive thyroid metastases will fare
less well.
Mean survival after surgery for thyroid metastasis is
approximately 2 years, with 42% 5-year overall sur-
vival.4,63 However, in the majority of those patients who
are selected for thyroid metastasectomy, long-term control
of the central neck can be achieved.
In the case of RCC, approximately 20% of these patients
are diagnosed with distant metastases at the time of diag-
nosis. Another 30% will go on to develop metastases
during follow-up, and some of these may present after a
significant delay of up to 20 years.66–68 Overall prognosis
for these patients is poor, but thyroid metastasectomy for
selected patients may offer good survival rates (30–50%),
and long disease-free intervals are reported.69 Hence, the
European Association of Urology guidelines support
treatment of thyroid metastases with surgery.70
Of the lung tumors known to metastasize to the thyroid,
non–small cell lung cancer is the most common type.71
With regard to breast cancer, 5 to 10% of cases present
with distant metastases at the time of diagnosis, and
occasionally these are in the thyroid.72,73 Evidence relating
to the management of thyroid metastases in cases of lung
and breast cancer is limited, though outcomes appear
poor.6,19,21,28,30–32,34–39,65
Colorectal cancer has also been reported to be associated
with a low incidence of thyroid metastases. One meta-
analysis identified 31 cases of thyroid metastases reported
between 1954 and 2006.74 These were usually accompa-
nied with multiorgan distant metastases, and hence,
prognosis was poor, with only a 50% survival at 1 year.74
Treatment for these patients was most commonly thy-
roidectomy with adjuvant chemotherapy, radiotherapy, or
both.60 The limited evidence available suggests that despite
being palliative, thyroidectomy in this setting was associ-
ated with reduced morbidity from thyroid-associated
respiratory symptoms.74 Melanoma has been associated
with thyroid metastases, and autopsy studies report an
incidence of up to 39%.5,7 Shimaoka et al. analyzed 2050
consecutive autopsy reports between 1955 and 1960. Six-
teen (39%) of 41 patients who died of malignant melanoma
had metastatic deposits in the thyroid gland.7 It is possible
that as therapy has improved for this disease, rates may
currently be lower. As is the case for other primary lesions,
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the literature mainly consists of case reports and case ser-
ies. Hence the management and likelihood of success are
undetermined. Additional case reports include small cell
lung cancers, pancreatic malignancies, and sarco-
mas.21,28,39,40,71 The majority of these presented with
multiple metastases against a background of aggressive
disease, and as such are inappropriate for thyroid surgery.
In summary, the literature lacks prospective randomized
trial evidence, and this is unlikely to ever be available.
Prognosis largely depends on the features of the primary
malignancy and the metastatic profile at the time of diag-
nosis—that is, timing, number, and location of metastases.
SURGICAL STRATEGY
A recent meta-analysis has suggested that those patients
managed with surgery experience better outcomes than
those managed expectantly.41 This was most apparent for
RCC, where median survival for those managed expec-
tantly was 6 months versus 27 months for those who
underwent surgery. However, it is likely that studies
included in this were subject to significant bias, with an
expectant approach favored in patients with more aggres-
sive disease.
For those patients considered to be candidates for sur-
gery, when considering the extent of thyroidectomy, the
aim should be to ensure removal of all gross disease with
an adequate margin. The procedure will therefore depend
on the extent of disease. In unilateral disease, most authors
recommend thyroid lobectomy rather than total thy-
roidectomy in order to minimize risk to the contralateral
recurrent laryngeal nerve and parathyroid glands (Table 2).
However, some authors suggest that lobectomy can be
associated with positive margins and therefore favor total
thyroidectomy.65 Russell et al. recently demonstrated a
decrease in recurrence for patients managed with total
thyroidectomy versus thyroid lobectomy (13 vs. 5%,
p\ 0.005), although studies included in this meta-analysis
are likely to have been subject to some selection bias.41 In
contrast to primary thyroid malignancy, metastases to the
gland are not sensitive to radioactive iodine; therefore, total
thyroidectomy is not mandatory as long as adequate mar-
gins are achieved. However, patients with multifocal
disease may require primary total thyroidectomy3,5 When
Russell et al. reported their own institutional experience of
17 patients with metastases to the thyroid, 4 (24%) had
bilateral disease.41 In the rare instance that multifocal
disease is identified after initial thyroid lobectomy, con-
sideration may be given to completion thyroidectomy.
Concomitant regional lymph node involvement is rare in
cases of metastasis to the thyroid; therefore, prophylactic
neck dissection is not recommended.58,60,65,75 However,
the regional lymphatics should be fully assessed preoper-
atively, particularly in RCC.68 RCC shows a tendency
toward vascular invasion, and involvement of the internal
jugular vein has been described both from nodal metastases
to the lymph nodes of the neck and from metastases to the
thyroid gland.65 For this reason, contrast-enhanced imaging
of the large vessels of the neck should be considered to
assess the relationship between disease and vasculature
before surgery.
Currently there is no evidence to support any other
adjuvant or alternative treatment to surgery.65 This is partly
because the most common primary tumor is RCC, which is
largely considered to be resistant to radiotherapy.76
SUMMARY
Autopsy and clinical series provide relevant data. Non-
thyroid metastases to the thyroid gland are rare in the
clinical setting, with the most common primary tumor
being RCC. In autopsy series, the most common primary
tumor is lung cancer. Thyroid involvement may be iden-
tified during initial staging, at follow-up imaging, or as a
new presentation of a neck mass. Preoperative evaluation is
similar to that for thyroid primary disease. Awareness of
previous malignancy is of significance and would be par-
ticularly helpful while assessing FNAC or core/open
biopsies. Prognosis will depend on the biology of the pri-
mary tumor, the burden/volume of metastases, the course
of disease, and any comorbidities. Communication
between oncologic teams is essential and influences deci-
sion making. In patients selected for surgery, thyroid
lobectomy with adequate margins may achieve control of
the central neck, whereas total thyroidectomy should be
reserved for large-volume or multifocal disease.
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